A First Study in Healthy Volunteers of a New Mobile Phone Application Measuring the Eyes Before and After Medication

Kontigo Care

Status: Completed

Conditions: Drug Abuse

Treatments: Device: Previct Drugs

Study type: Interventional

Funder types: Industry

Identifiers

NCT05731999

KCClin01

Details and patient eligibility

About

This is a pre-market, explorative, early feasibility, pilot, controlled clinical investigation designed to collect initial clinical data on the medical device Previct Drugs.

Full description

This first study will give valuable information on the feasibility of Previct Drugs function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of a medicinal product. It will also provide information on the usability of the device. Drug intake will in this first investigation be simulated by a controlled single application of commonly therapeutically used medicinal products from the following classes of drugs: phenethylamines (D1), benzodiazepines (D2), cannabinoids (D3), and opioids (D4).

Enrollment: 48 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or female healthy volunteers
• Age 18 to 70 years
• BMI between 18.5-30 kg/m2
• Weight between 50-100 kg
• Healthy as determined by the investigator or designee based on pre-study medical and surgical history and a health examination at enrollment
• Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to enrollment) must have a negative urine pregnancy test at enrollment and at visit 2 and must agree to use a medically acceptable contraception from enrollment until study completion
• No current drug usage defined as a negative urine drug test at enrollment and at visit 2
• Able to use Previct Drugs after initial training (defined as successfully performing a test after trying maximum three times per measurement)
• Been informed of the nature, the scope, and the relevance of the clinical investigation
• Voluntarily agreed on participation and has duly singed the Informed Consent Form

Exclusion criteria

• Participating in another clinical investigation which may affect the study outcome according to clinical judgement
• Pregnancy or Lactating
• Blind
• Deaf
• Abnormal ECG (QTc time >450 ms) at enrollment
• Current or recent history of alcohol misuse assessed by AUDIT where ≥6 points for women or ≥8 points for men indicates a potential misuse
• Current or history of psychiatric disorder or drug misuse assessed by M.I.N.I where the outcome will be based on clinical judgement
• Any disease or condition that may influence pupillary reflexes based on clinical judgement
• Undergone eye surgery that may influence pupillary reflexes based on clinical judgement
• Ongoing treatment with medications which may interfere with eye measurements based on clinical judgement
• Ongoing treatment with medications which may interfere with any of the medicinal products to be used
• History or presence of allergy or serious reaction to the medicinal products to be used
• History or presence of cardiovascular disease, e.g., arteriosclerosis, hypertension, or cor pulmonale
• History or presence of sleep-related breath disorder
• History or presence of gastrointestinal disease, e.g., paralytic ileus, acute abdomen, delayed gastric emptying, or chronic constipation
• History or presence of pulmonary disease, e.g., acute pulmonary insufficiency, severe respiratory depression with hypoxia, chronic obstructive lung disease, or bronchial asthma
• History or presence of autoimmune neuromuscular disease, e.g., myasthenia gravis
• Not able to read or understand the local language
• Any other condition that as judged by the investigator may make the follow-up or investigation inappropriate
• That according to the Declaration of Helsinki is deemed unsuitable for study enrollment

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

48 participants in 4 patient groups

Single application of phenethylamines (D1)

Experimental group

Description:

Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of phenethylamines.

Treatment:

Device: Previct Drugs

Single application of benzodiazepines (D2)

Experimental group

Description:

Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of benzodiazepines.

Treatment:

Device: Previct Drugs

Single application of cannabinoids (D3)

Experimental group

Description:

Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of cannabinoids.

Treatment:

Device: Previct Drugs

Single application of opioids (D4)

Experimental group

Description:

Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of opioids.

Treatment:

Device: Previct Drugs